Treatment of Pulmonary DS-TB in Patients Aged 12 or Older with Body Weight Over 40 kg

This protocol defines the recommended management approach for pulmonary drug-susceptible tuberculosis (DS-TB) in a well-defined patient population based on age and body weight thresholds.

Patient scenario

Eligible patients: Aged 12 years or older, body weight more than 40 kg, confirmed pulmonary DS-TB — and not pregnant, breastfeeding, or postpartum.

Treatment approach

A short-course, multi-drug oral combination regimen is used for this population, administered daily with food. The full drug combination, phase structure, and administration details are in the complete protocol.

Treatment goals

Conversion of sputum smear and culture to negative
Clinical and radiological improvement

Instant Access to Structured Evidence-Based Regimens

References

Patients aged 12 years or older with pulmonary DS-TB may receive a 4-month regimen of isoniazid, rifapentine, moxifloxacin and pyrazinamide (2HPMZ/2HPM).

Adults and children aged 12 years or older with a body weight of more than 40 kg and affected by pulmonary DS-TB are eligible for this regimen, including those who are also HIV-positive with a CD4 count of more than 100 cells/mm3 and patients with diabetes.

Patients aged 12 years or more with pulmonary DS-TB may receive the 4-month regimen 2HPMZ/2HPM, which comprises rifapentine, isoniazid, pyrazinamide and moxifloxacin (2 months of isoniazid, rifapentine, moxifloxacin and pyrazinamide, followed by 2 months of isoniazid, rifapentine and moxifloxacin).

The dose of rifapentine used was fixed at 1200 mg and moxifloxacin at 400 mg.

NTPs need to monitor patients' condition with regular clinical follow-ups and may perform at least smear microscopy after 2 months of treatment to monitor treatment response bacteriologically.

View source ↗